[Inhaled chemotherapy - Part 2: Clinical practice and potential applications]. / La chimiothérapie inhalée partie 2 : clinique et applications potentielles.
Rev Mal Respir
; 35(4): 378-389, 2018 Apr.
Article
en Fr
| MEDLINE
| ID: mdl-29731374
Lung tumours have a high incidence and cause many deaths worldwide. Despite progresses in treatment with targeted therapies and immunotherapies, the global 5-year survival rate remains low. In this context, inhaled chemotherapy could provide a means to intensify current therapeutic modalities. This review is based on clinical studies of inhaled chemotherapy against lung tumours. The advantages of this approach in terms of pharmacokinetic ratio and therapeutic index are presented as well as the limitations including contraindications and pulmonary side effects. Moreover, the challenges linked to technical aspects around administration are identified (inhalation device and facilities to limit aerosol propagation and exposure of healthcare professionals). The current developments proposed to overcome these challenges are described briefly. Also discussed are the potential applications for the distribution of the inhaled anticancer drug into tumour-bearing respiratory tracts and finally the potential indications for current therapeutic modalities.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pautas de la Práctica en Medicina
/
Aerosoles
/
Neoplasias Pulmonares
/
Antineoplásicos
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
Fr
Revista:
Rev Mal Respir
Año:
2018
Tipo del documento:
Article
País de afiliación:
Bélgica
Pais de publicación:
Francia